Evidence map›Paper›PMID 38665538›Full record

ArticleChemical science2024

A novel bioresponsive self-immolative spacer based on aza-quinone methide reactivity for the controlled release of thiols, phenols, amines, sulfonamides or amides.

Elena Ermini, Annalaura Brai, Elena Cini, Federica Finetti, Giuseppe Giannini, Daniele Padula, Lucrezia Paradisi, Federica Poggialini, Lorenza Trabalzini, Paola Tolu and 1 more

Open access · diamondAbstract read
In one paragraph

Article in Chemical science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Advances in the Release of Amide-Containing Molecules.Chemistry (Weinheim an der Bergstrasse, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Elena ErminiDipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena Via A. Moro 2 53100 Siena Italy maurizio.taddei@unisi.it.ORCID https://orcid.org/0000-0001-6506-5049
Annalaura BraiDipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena Via A. Moro 2 53100 Siena Italy maurizio.taddei@unisi.it.ORCID https://orcid.org/0000-0001-6395-9348
Elena CiniDipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena Via A. Moro 2 53100 Siena Italy maurizio.taddei@unisi.it.ORCID https://orcid.org/0000-0003-4420-8930
Federica FinettiDipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena Via A. Moro 2 53100 Siena Italy maurizio.taddei@unisi.it.
Giuseppe GianniniTranslational Medicine & Clinical Pharmacology Corporate R&D - Alfasigma SpA Via Pontina, km 30400 00071 Pomezia (Roma) Italy.
Daniele PadulaDipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena Via A. Moro 2 53100 Siena Italy maurizio.taddei@unisi.it.ORCID https://orcid.org/0000-0002-7171-7928
Lucrezia ParadisiDipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena Via A. Moro 2 53100 Siena Italy maurizio.taddei@unisi.it.
Federica PoggialiniDipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena Via A. Moro 2 53100 Siena Italy maurizio.taddei@unisi.it.
Lorenza TrabalziniDipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena Via A. Moro 2 53100 Siena Italy maurizio.taddei@unisi.it.
Paola ToluDipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena Via A. Moro 2 53100 Siena Italy maurizio.taddei@unisi.it.
Maurizio TaddeiDipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena Via A. Moro 2 53100 Siena Italy maurizio.taddei@unisi.it.ORCID https://orcid.org/0000-0001-8660-7580
University of Siena · ITAlfasigma (Italy) · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A stimuli-sensitive linker is one of the indispensable components of prodrugs for cancer therapy as it covalently binds the drug and releases it upon external stimulation at the tumour site. Quinone methide elimination has been widely used as the key transformation to release drugs based on their nucleofugacity. The usual approach is to bind the drug to the linker as a carbamate and release it as a free amine after a self-immolative 1,6-elimination. Although this approach is very efficient, it is limited to amines (as carbamates), alcohols or phenols (as carbonates) or other acidic functional groups. We report here a self-immolative spacer capable of directly linking and releasing amines, phenols, thiols, sulfonamides and carboxyamides after a reductive stimulus. The spacer is based on the structure of (5-nitro-2-pyrrolyl)methanol (NPYM-OH), which was used for the direct alkylation of the functional groups mentioned above. The spacer is metabolically stable and has three indispensable sites for bioconjugation: the bioresponsive trigger, the conjugated 1,6 self-immolative system and a third arm suitable for conjugation with a carrier or other modifiers. Release was achieved by selective reduction of the nitro group over Fe/Pd nanoparticles (NPs) in a micellar aqueous environment (H

Identifiers

PMID38665538
PMCPMC11041255
OpenAlexW4393634963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.